Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaomu pellets
- Development stage
- Unknown
- Lead developer
- Affiliated Hospital of Shaanxi University of Chinese Medicine
- Administration
- Oral
01
Overview
Xiaomu pellets is a Traditional Chinese Medicine (TCM) formulation developed by the Affiliated Hospital of Shaanxi University of Chinese Medicine for the treatment of non-alcoholic steatohepatitis (NASH). It is specifically indicated for patients presenting with the TCM syndrome pattern of spleen deficiency with phlegm and blood stasis. The formulation aims to improve liver function and reduce hepatic fat accumulation, as measured by the liver-to-spleen CT ratio. It has been evaluated in clinical trials in China comparing its efficacy and safety against polyene phosphatidylcholine in adults with NASH.
- Other names
- Xiaomu granulesXiaomu keli消木颗粒
Beyond the preview
Go deeper on Xiaomu pellets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaomu pellets.